0000014272-19-000212.txt : 20191127
0000014272-19-000212.hdr.sgml : 20191127
20191127173116
ACCESSION NUMBER: 0000014272-19-000212
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20191120
FILED AS OF DATE: 20191127
DATE AS OF CHANGE: 20191127
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: AHMED NADIM
CENTRAL INDEX KEY: 0001731193
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-01136
FILM NUMBER: 191259189
MAIL ADDRESS:
STREET 1: C/O CELGENE CORPORATION
STREET 2: 86 MORRIS AVENUE
CITY: SUMMIT
STATE: NJ
ZIP: 07901
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BRISTOL MYERS SQUIBB CO
CENTRAL INDEX KEY: 0000014272
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 220790350
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 430 E. 29TH STREET
STREET 2: 14 FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10016
BUSINESS PHONE: 2125464000
MAIL ADDRESS:
STREET 1: 430 E. 29TH STREET
STREET 2: 14 FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10016
FORMER COMPANY:
FORMER CONFORMED NAME: BRISTOL MYERS CO
DATE OF NAME CHANGE: 19891012
4
1
wf-form4_157489385725608.xml
FORM 4
X0306
4
2019-11-20
0
0000014272
BRISTOL MYERS SQUIBB CO
BMY
0001731193
AHMED NADIM
430 E. 29TH STREET
14TH FLOOR
NEW YORK
NY
10016
0
1
0
0
President, Hematology
Common Stock, $0.10 par value
2019-11-20
4
A
0
14819
0
A
14819
D
Common Stock, $0.10 par value
2019-11-20
4
A
0
1966
0
A
1966
I
401(k)
Option (right to buy)
19.55
2019-11-20
4
A
0
3255
0
A
2022-01-30
Common Stock, $0.10 par value
3255.0
3255
D
Option (right to buy)
19.61
2019-11-20
4
A
0
10460
0
A
2022-04-30
Common Stock, $0.10 par value
10460.0
10460
D
Option (right to buy)
19.72
2019-11-20
4
A
0
10464
0
A
2022-10-31
Common Stock, $0.10 par value
10464.0
10464
D
Option (right to buy)
21.63
2019-11-20
4
A
0
16740
0
A
2022-12-17
Common Stock, $0.10 par value
16740.0
16740
D
Option (right to buy)
26.6
2019-11-20
4
A
0
10463
0
A
2023-01-28
Common Stock, $0.10 par value
10463.0
10463
D
Option (right to buy)
31.85
2019-11-20
4
A
0
6974
0
A
2023-04-29
Common Stock, $0.10 par value
6974.0
6974
D
Option (right to buy)
38.35
2019-11-20
4
A
0
6975
0
A
2023-07-29
Common Stock, $0.10 par value
6975.0
6975
D
Option (right to buy)
42.0
2019-11-20
4
A
0
6975
0
A
2023-10-28
Common Stock, $0.10 par value
6975.0
6975
D
Option (right to buy)
43.85
2019-11-20
4
A
0
7440
0
A
2023-12-02
Common Stock, $0.10 par value
7440.0
7440
D
Option (right to buy)
39.95
2019-11-20
4
A
0
6974
0
A
2024-02-03
Common Stock, $0.10 par value
6974.0
6974
D
Option (right to buy)
47.12
2019-11-20
4
A
0
13949
0
A
2024-07-28
Common Stock, $0.10 par value
13949.0
13949
D
Option (right to buy)
55.44
2019-11-20
4
A
0
6975
0
A
2024-10-27
Common Stock, $0.10 par value
6975.0
6975
D
Option (right to buy)
62.67
2019-11-20
4
A
0
9350
0
A
2024-12-19
Common Stock, $0.10 par value
9350.0
9350
D
Option (right to buy)
63.41
2019-11-20
4
A
0
7012
0
A
2025-02-02
Common Stock, $0.10 par value
7012.0
7012
D
Option (right to buy)
58.78
2019-11-20
4
A
0
9350
0
A
2025-05-04
Common Stock, $0.10 par value
9350.0
9350
D
Option (right to buy)
70.89
2019-11-20
4
A
0
9350
0
A
2025-07-27
Common Stock, $0.10 par value
9350.0
9350
D
Option (right to buy)
61.01
2019-11-20
4
A
0
9350
0
A
2025-11-09
Common Stock, $0.10 par value
9350.0
9350
D
Option (right to buy)
54.2
2019-11-20
4
A
0
9299
0
A
2026-02-01
Common Stock, $0.10 par value
9299.0
9299
D
Option (right to buy)
56.44
2019-11-20
4
A
0
5812
0
A
2026-05-02
Common Stock, $0.10 par value
5812.0
5812
D
Option (right to buy)
61.34
2019-11-20
4
A
0
5843
0
A
2026-08-01
Common Stock, $0.10 par value
5843.0
5843
D
Option (right to buy)
54.94
2019-11-20
4
A
0
12205
0
A
2026-10-31
Common Stock, $0.10 par value
12205.0
12205
D
Option (right to buy)
60.53
2019-11-20
4
A
0
12272
0
A
2027-01-30
Common Stock, $0.10 par value
12272.0
12272
D
Option (right to buy)
66.35
2019-11-20
4
A
0
5843
0
A
2027-05-01
Common Stock, $0.10 par value
5843.0
5843
D
Option (right to buy)
72.42
2019-11-20
4
A
0
5843
0
A
2027-07-31
Common Stock, $0.10 par value
5843.0
5843
D
Option (right to buy)
54.29
2019-11-20
4
A
0
9300
0
A
2027-10-30
Common Stock, $0.10 par value
9300.0
9300
D
Option (right to buy)
55.52
2019-11-20
4
A
0
9299
0
A
2028-01-29
Common Stock, $0.10 par value
9299.0
9299
D
Option (right to buy)
44.7
2019-11-20
4
A
0
19619
0
A
2028-05-08
Common Stock, $0.10 par value
19619.0
19619
D
Option (right to buy)
47.81
2019-11-20
4
A
0
19619
0
A
2028-07-30
Common Stock, $0.10 par value
19619.0
19619
D
Option (right to buy)
38.41
2019-11-20
4
A
0
19621
0
A
2028-10-29
Common Stock, $0.10 par value
19621.0
19621
D
Restricted Stock Units
2019-11-20
4
A
0
2908
0
A
2020-05-01
Common Stock, $0.10 par value
2908.0
2908
D
On November 20, 2019 ("Closing Date"), Bristol-Myers Squibb Company ("BMS") completed the previously announced acquisition of Celgene Corporation ("Celgene") contemplated pursuant to the terms and conditions of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 2, 2019, by and among BMS, Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), and Celgene. Under the Merger Agreement, Merger Sub merged with and into Celgene with Celgene surviving as a direct wholly owned subsidiary of BMS (the "Merger"). The transactions on this form were not reported in a timely manner due to an administrative delay in calculations surrounding the total Merger Consideration (defined below) received by the Reporting Person.
Pursuant to the Merger, each outstanding share of Celgene common stock, par value $0.01 per share, was converted into the right to receive (x) $50 in cash, without interest, (y) one share of BMS common stock, par value $0.10 per share and (z) one tradeable contingent value right ( "CVR") per share or, with respect to equity awards (in some cases), per share underlying each such equity award ("Merger Consideration"). Each CVR will represent the right to receive $9.00 in cash upon Federal Drug Administration ("FDA") approval of a specified set of milestones, as set forth in the Contingent Value Rights Agreement, dated as of November 20, 2019, between BMS and Equiniti Trust Company, as trustee.
Based on a plan statement as of the end of the most recent fiscal quarter.
All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement.
Each restricted stock unit converts into one share of common stock upon vesting.
The restricted stock unit vests in three equal annual installments beginning on May 1, 2018.
ONE OF TWO (1 OF 2) FORM 4s BEING FILED TO REPORT TRANSACTIONS OCCURRING ON NOVEMBER 20, 2019.
/s/ Lisa A. Atkins, attorney-in-fact for Nadim Ahmed
2019-11-27